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Abstract: In this review, we summarize the recent literature on dapEencoded N-succinyl-L,L-diaminopimelic acid desuccinylase (DapE) enzymes,
with an emphasis on structure–function studies that provide insight into the
catalytic mechanism. Crystallographic data have also provided insight into
residues that might be involved in substrate and hence inhibitor recognition
and binding. These data have led to the design and synthesis of several new
DapE inhibitors, which are described along with what is known about how
inhibitors interact with the active site of DapE enzymes, including the efficacy
of a moderately strong DapE inhibitor.
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Introduction
The emergence of antibiotic-resistant bacterial infections has
created a significant and growing medical problem throughout the
world [1–5]. Antibiotic resistance has been recognized since the
introduction of penicillin more than 50 years ago, when penicillinresistant infections caused by Staphylococcus aureus rapidly appeared
[3, 6]. Because bacteria have been exposed to many of the currently
available antibiotics such as β-lactams, fluoroquinolones, macrolides,
tetracyclines, aminoglycosides, glycopeptides, and trimethoprim
combinations for years, they have evolved resistance to these drugs
owing to mutation of genes or the acquisition of genes that impart
resistance from other organisms [3, 7–10]. In fact, several pathogenic
bacteria, some of which were thought to have been eradicated, have
made a significant resurgence owing to resistance to antibiotics [3, 6].
For example, tuberculosis is currently the leading cause of death in
adults by an infectious disease worldwide, which is significant given
that death rates due to tuberculosis had declined to near imperceptible
levels in industrial nations [11–13]. According to the Centers for
Disease Control and Prevention, several bacterial strains currently
exhibit multi-drug resistance, with more than 60 % of hospitalacquired infections in the USA caused by the so-called ESKAPE
pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and
Enterobacter species).
Antibiotics work by interfering with a vital bacterial cell function
at a specific cellular target by either killing the bacteria or arresting
their multiplication [5]. This allows the patient’s immune system to
clear the bacteria from the body. Inhibitors of cell wall biosynthesis
(vancomycin and β-lactams, for example) have proven to be very
potent antibiotics, providing evidence that interfering with cell wall
synthesis has deleterious effects on bacterial cell survival. Enzymes
that are targeted by these antibiotics tend to be present in all bacteria
and are highly similar in structure and function, such that certain
antibiotics kill or inhibit the growth of a broad range of bacterial
species (i.e., broad-spectrum antibiotics) [3, 7–10]. Unfortunately,
only two new classes of antibacterial drugs have emerged since 1962.
According to the Infectious Diseases Society of America, at least ten
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new systemic antibacterial drugs should enter the market by 2020, but
most of these are derivatives of existing classes of antibiotics. Since
every antibiotic has a finite lifetime, as resistance will ultimately occur,
particularly if the same enzymes are repeatedly targeted, development
of new classes of inhibitors that target previously untargeted cellular
enzymes is essential to retain control of infectious disease [14, 15].

Lysine biosynthetic pathway
From bacterial genetic information, the meso-diaminopimelate
(m-DAP)/lysine biosynthetic pathway offers several potential
antibacterial enzyme targets that have yet to be explored (Fig. 1) [16–
21]. One of the products of this pathway, lysine, is required in protein
synthesis and is also used in the peptidoglycan layer of Gram-positive
bacterial cell walls. A second product of this pathway, m-DAP, is an
essential component of the peptidoglycan cell wall for Gram-negative
bacteria, providing a link between poly-saccharide strands. Since
lysine is an essential amino acid and is not synthesized by humans, it
must be ingested. However, most bacteria, plants, and algae
synthesize lysine and m-DAP from aspartic acid through three related
pathways that diverge after the production of L-tetrahydrodipicolinate
[16, 17, 22]. The presence of multiple biosynthetic pathways in
bacteria for the synthesis of m-DAP/lysine highlights the importance of
m-DAP/lysine for bacterial cell survival.
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Fig. 1 Biosynthetic pathways of meso-diaminopimelic acid and lysine in
bacteria

The succinylase pathway is the primary biosynthetic pathway for
m-DAP/lysine and is used by all Gram-negative and most Grampositive bacteria [16]. The dehydrogenase pathway forms m-DAP
directly from L-tetrahydrodipicolinate, but this is a high-energy
transformation and is limited to only a few Bacillus species [16]. The
acetylase pathway is also a minor biosynthetic pathway for m-DAP
production and is also limited to only a few Bacillus species [17]. One
of the enzymes in the succinylase pathway, the dapE-encoded Nsuccinyl-L,L-diaminopimelic acid desuccinylase (DapE), is a Zn(II)containing metallohydrolase. It has been shown that deletion of the
gene encoding DapE is lethal to Helicobacter pylori and Mycobacterium
smegmatis [23, 24]. Even in the presence of lysine-supplemented
media, H. pylori was unable to grow, suggesting that lysine cannot be
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synthesized by other pathways or imported. Therefore, DapE enzymes
appear to be essential for cell growth and proliferation and are part of
a biosynthetic pathway that is the only source of lysine in most
bacteria. Since there are no similar biosynthetic pathways in
mammals, DapE enzymes appear to be potential targets for inhibitors
that may possess antimicrobial activity [16].

DapE enzymes contain a dinuclear Zn(II) active
site
DapE enzymes catalyze the hydrolysis of N-succinyl-L,Ldiaminopimelic acid (L,L-SDAP), forming L,L-diaminopimelic acid and
succinate (Fig. 2) [22]. DapE enzymes have been purified from
multiple sources and genes have been identified in a large number of
pathogenic Gram-positive and Gram-negative bacteria, including all of
the ESKAPE pathogens [23–28]. Alignment of several of the DapE
gene sequences shows a minimum of 49 % identity [29]. Significantly,
all of the residues that are metal binding ligands in the M28 family of
dinuclear Zn(II)-dependent metalloproteases [30], including the
aminopeptidase from Vibrio proteolyticus (Aeromonas proteolytica,
AAP) and carboxypeptidase G2 from Pseudomonas sp. strain-RS-16
(CPG2) [31, 32], are strictly conserved in all DapE enzymes. Since the
catalytic activity of DapE enzymes requires Zn(II), and both CPG2 and
AAP possess (μ-aquo)(μ-carboxylato)dizinc(II) active sites with one
terminal carboxylate and one histidine residue at each metal site, a
similar active site was proposed for DapE enzymes [22, 33–35].
Evidence for a dinuclear Zn(II) active site in DapE enzymes was
obtained via zinc K-edge extended X-ray absorption fine structure
(EXAFS) spectra of the DapE from Haemophilus influenzae in the
presence of 1 and 2 equiv of Zn(II) (i.e., [Zn_(DapE)] and
[ZnZn(DapE)]) [36]. Fourier transforms of the zinc EXAFS spectrum
are dominated by a peak at approximately 2.0 Å, which was best fit
assuming approximately five (N,O) scatterers at 1.96 and 1.98 Å for
[Zn_(DapE)] and [ZnZn(DapE)], respectively. Inclusion of a sulfur
atom provided poorer fits based on Debye–Waller factors. A secondshell feature at approximately 3.34 Å appears in the [ZnZn(DapE)]
EXAFS spectrum but is significantly diminished in the [Zn_(DapE)]
EXAFS spectrum. These data confirmed that DapE enzymes can bind
two Zn(II) ions that form a dinuclear site.
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Fig. 2 Reaction catalyzed by dapE-encoded N-succinyl-L,L-diaminopimelic
acid desuccinylase (DapE)

Both AAP and CPG2 contain active-site histidine residues that
function as ligands to the Zn1 and Zn2 centers. On the basis of
sequence alignment of the DapE from H. influenzae with AAP and
CPG2, both H67 and H349 were predicted to be Zn(II) ligands [29]. In
an effort to clearly define the active-site residues and provide insight
into the structural properties of each divalent metal ion in DapE
enzymes, the H67A and H349A DapE mutant enzymes were prepared.
The H67A DapE enzyme exhibited a decrease in catalytic efficiency
(about 180-fold) compared with wild-type DapE toward the substrate
L,L-SDAP. No catalytic activity was observed for H349A under the
experimental conditions used. Electron paramagnetic resonance (EPR)
and UV–vis data indicated that the Co(II) ion bound to H349A DapE is
analogous to that of wild-type DapE after the addition of a single
Co(II) ion. The addition of 1 equiv of Co(II) to H67A DapE provided
spectra that are very different from the spectrum for the first Co(II)
binding site of the wild-type enzyme, but are similar to the spectrum
for the second binding site. The UV–vis and EPR data, in conjunction
with the kinetic data, are consistent with the assignment of H67 and
H349 as active-site metal ligands for DapE. Furthermore, these data
suggest that H67 is a ligand in the first metal binding site, whereas
H349 resides in the second metal binding site.
Sequence alignment with AAP and CPG2 also suggested that the
active-site residue in the DapE from H. influenzae, E134, likely
functions as the general acid/base during the hydrolysis reaction
catalyzed by DapE [22]. To elucidate the catalytic role of E134, the
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E134A and E134D mutant DapE enzymes were prepared [37]. The
Michaelis constant (Km) was found not to change upon substitution
with aspartate but the kcat values changed drastically in the following
order: glutamate (140 s−1), aspartate (0.13 s−1), and alanine (none
detected). Examination of the pH dependence of the kinetic constants
kcat and Km for the E134D enzyme revealed ionizations at pH 6.4, 7.4,
and approximately 9.7. Isothermal titration calorimetry studies on
wild-type DapE provided Kd values for the first and second Zn(II)
binding sites of 4.4 and 13.6 μM. Isothermal titration calorimetry
experiments on E134D DapE and E134A DapE revealed a statistically
significant in metal Kd values of 2.9 and 1.4 times, respectively, for the
first metal binding event. Interestingly, UV–vis and EPR spectra
obtained on Co(II)-substituted E134D and E134A DapE did not reveal
any significant changes, suggesting that both Co(II) ions reside in
distorted trigonal bipyramidal coordination geometries [38].
Combination of these data indicates that E134 is intrinsically involved
in the hydrolysis reaction catalyzed by DapE and likely plays the role of
a general acid/base.

Structural characterization of DapE enzymes
A major limitation in developing a previously undescribed class
of antimicrobials that target DapE enzymes was the lack of knowledge
about their active-site structure, including potential residues involved
in substrate binding. The X-ray crystal structure of the DapE from
Neisseria meningitidis was reported at 1.9-Å resolution, but the DapE
was in the apo form, providing little information about the Zn(II)
active site [39]. Recently, the X-ray crystal structure of the DapE from
H. influenzae was reported for both the mono and dinuclear Zn(II)
forms at 2.0- and 2.3-Å resolution, respectively [40]. Similar to the
DapE from N. meningitidis, the DapE from H. influenzae forms a
homodimer where the catalytic domain consists of an α/β globular
domain with a twisted β-sheet hydrophobic core sandwiched between
α-helices (Fig. 3). The active-site cleft is located in the center of the
catalytic domain above the centrally located parallel strands of the βsheet and is covered by loops. The location and the architecture of the
active site are strikingly similar to those of the active sites of CPG2
and AAP [28, 29].
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Fig. 3 Ribbon diagram of the X-ray crystal structure of the DapE from
Haemophilus influenzae showing the dimer and catalytic structural domains.
Zinc ions are shown in black (Zn1, the catalytic zinc) and gray (Zn2)

The active site of the mononuclear Zn(II) form of DapE
([Zn_(DapE)]) reveals that Zn1 resides in a distorted tetrahedral
geometry coordinated by the carboxylate oxygens of D100 and E163
as well as one nitrogen atom of H67 (Fig. 4). The remaining
coordination site is filled by an oxygen atom provided from a water
molecule. In the dinuclear Zn(II) form of DapE ([ZnZn(DapE)]), the
active site contains two Zn(II) ions at an interatomic distance of 3.36
Å, compared with 3.45 Å for AAP and 3.25 Å for CPG2 [31, 32]. Each
of the Zn(II) ions adopts a distorted tetrahedral geometry and is
coordinated by one imidazole group (H67 for Zn1 and H349 for Zn2)
and one carboxylate group (E163 for Zn1 and E135 for Zn2). Both
Zn(II) ions are bridged by an additional carboxylate group (D100) on

Journal of Biological Inorganic Chemistry, Vol. 18, No. 2 (February 2013): pg. 155-163. DOI. This article is © Springer and
permission has been granted for this version to appear in e-Publications@Marquette. Springer does not grant permission
for this article to be further copied/distributed or hosted elsewhere without the express permission from Springer.

8

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

one side and water/hydroxide on the opposite side, forming a (μaquo)(μ-carboxylato)dizinc(II) core with one terminal carboxylate and
one histidine residue at each metal site. These structures confirm the
assignment of H67 and H349 as active-site ligands, with H67 residing
in the first metal binding site, as well as the role of Glu134.

Fig. 4 Active sites of a the mononuclear Zn(II) form of DapE and b the
dinuclear Zn(II) form of DapE from H. influenzae

Inspection of the X-ray crystal structures of [Zn_(DapE)] and
[ZnZn(DapE)] combined with surface analysis revealed a crescentshaped cavity that extends along the catalytic domain and surrounds
the active site (Fig. 5). This well-defined, negatively charged cavity is
shaped from the top by strand β12 and α8 and in the middle by a loop
connecting these two elements. The bottom of the cavity is formed by
a loop connecting strands β6 and β7, and a loop connecting β5 and α4.
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Taking into account the linear character of the substrate, we think it is
likely that the substrate binds in an extended conformation [41], lining
up along the grove with the peptide bond positioned over the activesite metals. It is conceivable that substrate binding is further stabilized
by interaction of the substrate carboxylate groups with positively
charged amino acid side chains. Potential candidates include K175,
R258, and R329 (Fig. 6). In the [ZnZn(DapE)] structure, R258 and
R329 form a charged dipole interaction with a sulfate ion, a possible
mimic of the carboxylic group of the substrate. R329 is centrally
positioned in a positively charged pocket that it forms together with
R258. Interestingly, the active-site pocket of CPG2 contains an
arginine that is conserved in DapE (R329) and has been proposed to
bind the carboxylate group of the side chain. These data, in
combination with the findings of reported inhibitor binding studies [35,
36, 42, 43], indicate that DapE is an excellent target for a highly
specific drug that should have high efficacy and low toxicity.

Fig. 5 Surface rendering of the dinuclear Zn(II) form of DapE from H.
influenzae showing the charge distribution and depicting the crescent-shaped
active-site cavity
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Fig. 6 Charged residues near the dinuclear active site of DapE that may play
a role in substrate recognition and binding

Proposed catalytic mechanism of DapE
The X-ray structures of [Zn_DapE] and [ZnZn_DapE] provide a
structural foundation for a proposed reaction mechanism of DapE [22,
35, 37]. Analysis of the available structures along with the previously
reported kinetic and spectroscopic data for DapE enzymes allowed a
detailed mechanism of catalysis for DapE enzymes to be proposed
(Fig. 7) [40]. On the basis of the proposed catalytic mechanism for
AAP [44, 45], the first step in catalysis for DapE enzymes is likely
recognition of the L,L-SDAP side chain by the crescent-shaped cavity
adjacent to the Zn1 site. Next, the peptide carbonyl oxygen of L,LSDAP coordinates to Zn1 and expands its coordination number from
four to five, activating the carbonyl for nucleophilic attack.
Deprotonation of the metal-bound water molecule by E134 to form a
nucleophilic hydroxide moiety is consistent with the postulated pKa of
the zinc-bound water molecule [22]. Once the zinc-bound hydroxide
has formed, it can attack the activated carbonyl carbon of the
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substrate, forming an γ-1-μ-transition-state complex [36]. Solvent
kinetic isotope effect studies yielded an inverse isotope effect that was
explained by the attack of a zinc-bound hydroxide on the amide
carbonyl [22]. E134 may provide a proton to the penultimate amino
nitrogen, similar to what is observed for AAP, returning it to its ionized
state and thus facilitating product release. Once the products have
been released, a water molecule bridging the two metal ions is
replaced. In the absence of the second metal ion, the catalytic
mechanism does not likely change markedly as H349 is in a position to
assist in orienting the substrate properly in the active site through the
formation of a hydrogen bond with a carboxylate side chain of the
substrate, thereby stabilizing the transition-state intermediate,
reminiscent of proposals for the monometalated forms of AAP and the
methionine aminopeptidase from Escherichia coli [46–48]. In the
presence of a dinuclear site, the second metal ion likely coordinates
either the peptide carbonyl oxygen in a bridging fashion or a
carboxylate side chain of the substrate.

Fig. 7 Proposed catalytic mechanism of a monozinc, and b dizinc DapE

Design and synthesis of DapE inhibitors
The design and synthesis of novel DapE inhibitors requires
information regarding substrate specificity. Therefore, the four isomers
of N-succinyldiaminopimelic acid (SDAP) as well as a number of
acetylated amino acids have been examined as potential substrates.
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DapE was not able to hydrolyze the D,D, L,D, or D,L isoforms of SDAP,
confirming that L,L-SDAP is the only known biological substrate for
DapE enzymes. Moreover, no hydrolytic degradation was observed for
any acetylated amino acids tested [28, 35]; thus, the DapE active site
has strict substrate specificity with regard to both functional groups
and stereochemistry. These data also suggest that the carboxylate of
the succinyl moiety forms an important interaction within the active
site of DapE since the acetylated amino acids could not be hydrolyzed.
Alternatively, the acetylated versions of these amino acids may
introduce a repulsive steric interaction because of bulky alkyl groups,
thus preventing hydrolysis. Given the lack of hydrolytic activity toward
SDAP isoforms, a series of potential DapE inhibitors based on SDAP
bearing different N-linked acyl side chains terminated with (1) a
carboxyl group or (2) a lipophilic moiety were synthesized.
Unfortunately, none of these compounds functioned as potent
inhibitors of DapE [35, 36, 42, 43]. Finally, D,L-succinyl aminopimelate
was examined; this differs from the natural substrate, L,L-SDAP, only
by the absence of the amine group on the amino acid side chain.
Interestingly, DapE could not hydrolyze this compound, implying that
the amine provides an important interaction for substrate binding.
The next step in inhibitor design for DapE enzymes involved
understanding how inhibitors bind to the active site. To date, no X-ray
structural data for a DapE enzyme in the presence of an inhibitor have
been reported; however, zinc K-edge EXAFS spectra of [ZnZn(DapE)]
in the presence of the competitive inhibitors 2-carboxyethylphosphonic
acid (CEPA; Ki = 800 μM) and 5-mercaptopentanoic acid (MSPA; Ki = 6
μM) have been reported [36]. Phosphonic acid containing compounds
have been shown to be potent inhibitors of metallohydrolases,
including AAP and the bovine lens leucine aminopeptidase, and have
been used as probes of the transition state of hydrolysis reactions. The
EXAFS data for [ZnZn(DapE)]–CEPA indicate that the average
coordination number of each Zn(II) ion is five, and the Zn–Zn distance
remains 3.34 Å. An increase in the M–M distance of [ZnZn(AAP)], from
3.5 to 3.9 Å, is observed upon the addition of the transition-state
analog inhibitor L-leucine phosphonic acid (LPA), which contains a
ligating group similar to that in CEPA [49]. The X-ray crystal structure
and EXAFS data for [ZnZn(AAP)]–LPA reveal that the bridging water
molecule is displaced by LPA, resulting in an γ-1,2-μ-phosphonate
bridge and an increase in the Zn–Zn distance of 0.4 Å. The fact that
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the Zn–Zn distance is not altered upon CEPA binding to [ZnZn(DapE)]
suggests an γ-1-μ-phosphonate bridge exists, similar to the binding
mode of LPA with regard to bovine lens leucine aminopeptidase [49,
50]. On the other hand, MSPA binding to [ZnZn(DapE)] has a marked
effect on the zinc K-edge, suggesting that the average electronic
environment of the dinuclear Zn(II) site has changed significantly. The
observed shift in the position of the absorption edge to lower energy is
indicative of a net increase in electron density at the dinuclear Zn(II)
site, consistent with a sulfur ligand. In addition, the EXAFS data for
[ZnZn(DapE)]–MSPA reveals a new feature at 2.3 Å that is highly
characteristic of a direct zinc–sulfur interaction. Moreover, the M–M
distance is lengthened from 3.34 to 3.64 Å. These data indicate that
the thiol group of MSPA binds to one or both of the Zn(II) ions in the
active site of DapE.
The fact that thiol-based molecules were shown to be
moderately strong inhibitors of DapE provided insight for examination
of bifunctional molecules that contained, in addition to a thiol zinc
binding group, a carboxylate moiety that could interact with the
positively charged lysine and arginine side chains that purportedly
reside near the active site. These studies led to the identification of
several low micromolar inhibitors of DapE, all of which, like MSPA,
contain a thiol functional group [42]. Thiol-containing compounds are
typically potent monodentate inhibitors of Zn(II) metalloproteins [51].
One of the better inhibitors was L-penicillamine (Fig. 8), which
exhibited an IC50 of 13.7 μM, and a measured Ki of 4.6 μM
(competitive). DapE is stereoselective with respect to recognition of
inhibitors, as D-penicillamine gave an IC50 of 50 μM. Given the success
with these carboxylic acid containing thiols, L-captopril (Fig. 8), an
angiotensin-converting enzyme inhibitor, was examined; it contains
the requisite zinc binding group and carboxylate functionalities. LCaptopril exhibited an IC50 of 3.3 μM and a measured Ki of 1.8 μM
(competitive). Again, the binding is stereoselective, as D-captopril was
an order of magnitude less potent, with an IC50 of 42.0 μM. Given the
good potency of L-captopril, another angiotensin-converting enzyme
inhibitor, enalapril, was screened but did not show any potency toward
DapE. 4-Mercaptobutyric acid is also an inhibitor of DapE and exhibits
an IC50 of 43 μM, whereas 2-mercaptobenzoic acid has a measured
IC50 of 34 μM. For these low micromolar inhibitors, it was hypothesized
that a negatively charged carboxylate in the molecule participates in
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an ionic interaction with a positively charged lysine or arginine near
the active site.

Fig. 8 Structures of L-captopril and L-penicillamine

Given that L-captopril functions as a moderately strong inhibitor
of DapE, its efficacy was examined using a standard plate assay [42].
Application of L-captopril or L-penicillamine directly to plates cultured
with E. coli showed a dose-responsive antibiotic activity for L-captopril.
Very little inhibition was observed for 1 mg of L-captopril, but amounts
of 5 and 20 mg demonstrated a clear positive antibiotic result. These
data suggest that L-captopril can cross the bacterial cell membrane
and function to inhibit bacterial cell growth. Whether DapE is the
cellular target of L-captopril was not addressed; however, a recent
study suggested that DapE is not the main target of L-captopril
antimicrobial activity since L-captopril inhibited Salmonella enterica
and E. coli in a DapE-independent manner [52]. Clearly, further
studies are needed to verify DapE as an antimicrobial target, and such
studies will necessitate the discovery of strong binding inhibitors that
are specific for DapE enzymes.

Concluding remarks
Bacterial infections, some of which were thought to be
eradicated, have made a significant resurgence owing to bacterial
resistance to all known antibiotics [2–4]. Consequently, new
compounds that combat these pathogens and target enzymes involved
in bacterial cell wall synthesis or pathways involved in cell replication
are in high demand [53–60]. The m-DAP/lysine biosynthetic pathway
offers several potential antibacterial targets that have yet to be
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explored. Although our understanding of the catalytic mechanism of
DapE has improved markedly over the past few years, the mechanism
has not yet been entirely delineated. For example, several substrate
binding steps have been proposed and the roles of each metal ion
during catalysis are still in question. Therefore, more experimental
evidence is needed to distinguish between the competing mechanistic
proposals for DapE. Even so, the results obtained from the studies
described in this review have provided new insight into the structure
and function of DapE enzymes and have led to new medicinal
chemistry leads. Additional insight into the catalytic mechanism of
DapE and the determinants of substrate binding will be critical for the
rational design of selective DapE inhibitors that may function as a new
class of antimicrobial agents.
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AAP

Aminopeptidase from Vibrio proteolyticus (Aeromonas proteolytica)

CEPA

2-Carboxyethylphosphonic acid

CPG2

Carboxypeptidase G2 from Pseudomonas sp. strain RS-16

DapE

dapE-encoded N-succinyl-L,L-diaminopimelic acid desuccinylase

EPR

Electron paramagnetic resonance

EXAFS

Extended X-ray absorption fine structure

L,L-SDAP

N-Succinyl-L,L-diaminopimelic acid, LPA, L-Leucine phosphonic acid

m-DAP

meso-Diaminopimelate

MSPA

5-Mercaptopentanoic acid

SDAP

N-Succinyldiaminopimelic acid
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